Zhiyi Biotechnology key facts
as of Oct 2026- Developer of live biotherapeutics designed to advance microbiome-based drug discovery and treatment development.
- Zhiyi Biotechnology is valued at approximately $676.3M as of Oct 2026 (last reported valuation).
- It has raised $107.7M; the latest was Later Stage VC in Apr 2026.
- Notable investors include Shenzhen Capital Group, Korea Investment Partners, Sinovation Ventures, Guangdong Technology Financial Group, Cathay Capital — 16 tracked in total.
- Status: Privately Held (backing).
Zhiyi Biotechnology's last reported valuation, Jul 2022. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch Zhiyi Biotechnology: the Monday email on marks, rounds and moves
Zhiyi Biotechnology funding rounds
No funding rounds for Zhiyi Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Zhiyi Biotechnology
16+Zhiyi Biotechnology valuation
Zhiyi Biotechnology's last reported valuation was $676 million in Jul 2022. No priced round, secondary trade or fund mark has surfaced since.
Zhiyi Biotechnology investors
16 investors are on record for Zhiyi Biotechnology, including Shenzhen Capital Group, Korea Investment Partners, Sinovation Ventures and Guangdong Technology Financial Group.
About Zhiyi Biotechnology
Developer of live biotherapeutics designed to advance microbiome-based drug discovery and treatment development. The company offers research microbial cultures and strains to develop effective treatments, is focused on unmet medical needs, and is dedicated to developing accessible drugs to benefit more patients, enabling healthcare professionals to prescribe better medicine.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2013
- Employees
- 150
- Website
- zypharm.com.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.